The results showed that the expression level of TFRC did not change in AML cells after treatment with selinexor (GSE199454, Fig. 6b), fedratinib (GSE199456, Fig. 6c), Tamibarotene (GSE155559, Fig. 6d), ATRA + TCP (combined with the LSD1 inhibitor tranylcypromine with all-trans retinoic acid, GSE151594, Fig. 6e), ORY-1001 (GSE182150, Fig. 6f), Ara-C or ABT199 (GSE178910, Fig. 6g). Here, TFRC is linked to acute myeloid leukemia.